ArticleFrontiers in neurology
The evaluation of Tenecteplase for the treatment of ischemic stroke (real-world data).
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The study reinforces the use of Tenecteplase (TNK) dosed at 0.25 mg/kg in real-world community settings as an effective and safe alternative to alteplase standard dosing. Objective: The aim of this study is to evaluate the effectiveness and safety of TNK compared to alteplase in a community healthcare setting for treating ischemic stroke, including patients with large vessel occlusion (LVO) who were candidates for mechanical thrombectomy, as well as those with non-large-vessel ischemic stroke. Design setting and participants: This was a multicenter, retrospective cohort study across 11 primary and comprehensive hospitals within the BayCare Health System in West Central Florida (December 2019-April 2024), comparing TNK 0.25 mg/kg (max 25 mg) with standard-dose alteplase among adults with acute ischemic stroke presenting within 4.5 h of last-known-well. A total of 476 patients were evaluated retrospectively, with 270 patients in the Alteplase arm and 206 patients in the TNK arm. Main outcome and measures: The primary outcome (LVO subgroup) was substantial early reperfusion prior to thrombectomy, defined as restoration of blood flow to >50% of the ischemic territory (mTICI 2b/2c/3) by CTA/MRA or absence of a retrievable thrombus at the initial angiographic assessment. A LVO was determined at the initial CT/CTA prior to the thrombectomy. Secondary outcomes included door-to-needle time (DTN), NIHSS at 24 h, discharge NIHSS, discharge disposition, 90-day mRS, and safety (symptomatic/asymptomatic ICH by system definitions and angioedema). Safety outcomes for ICH were assessed using the SITS-MOST criteria for symptomatic ICH including subarachnoid hemorrhage within 24 h of treatment combined with an increase from baseline in NIHSS score of at least 4 points. Results: Of the 476 AIS patients (TNK Conclusion and relevance: In a community-hospital system, TNK 0.25 mg/kg IV was associated with higher pre-thrombectomy reperfusion in LVO, shorter door-to-needle times, comparable safety, and improved functional outcomes versus alteplase in key analyses. These findings align with recent randomized evidence and support TNK 0.25 mg/kg as an effective alternative to alteplase for AIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.